How many insider trades does FilingIQ track for EBS?

FilingIQ tracks 1,016 Form 4 insider transactions for EBS (Emergent BioSolutions Inc.), covering filings from Jan 20, 2015 onwards. 52 of those were filed in the last 90 days.

Are EBS insiders net buyers or net sellers?

Across the full Form 4 history for EBS, 2 transactions (0%) were open-market purchases and 279 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does EBS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is EBS in?

Emergent BioSolutions Inc. (EBS) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $583.66M.

EBS insider trading

NYSE Healthcare

Emergent BioSolutions Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

1,016

Last 90 days

Buys / sells

0% / 27%

Market cap

$583.66M

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Company website: www.emergentbiosolutions.com

EBS insider activity at a glance

FilingIQ has scored 1,016 insider transactions for EBS since Jan 20, 2015. The most recent filing in our index is dated May 1, 2026.

Across the full history, 2 open-market purchases and 279 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on EBS insider trades is 57.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live EBS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Politicians who have traded EBS

Cohen, Steve

U.S. Rep. , TN · 157 trades

Frequently asked

How many insider trades does FilingIQ track for EBS?: FilingIQ tracks 1,016 Form 4 insider transactions for EBS (Emergent BioSolutions Inc.), covering filings from Jan 20, 2015 onwards. 52 of those were filed in the last 90 days.
Are EBS insiders net buyers or net sellers?: Across the full Form 4 history for EBS, 2 transactions (0%) were open-market purchases and 279 (27%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does EBS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is EBS in?: Emergent BioSolutions Inc. (EBS) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $583.66M.

Methodology & sources

Every EBS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.